학술논문
IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S387-S388
Subject
Language
ISSN
2152-2650